Tokyo, Sept 12, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the new mask spray Crystal Veil(R) Bokin 24 (classified as miscellaneous goods) on Tuesday, September 18. Crystal Veil Mask Bokin 24, which contains the long-acting antimicrobial agent Etak(R), is sprayed onto face masks prior to use, making it difficult for viruses and bacteria to adhere to the mask surface for a prolonged period of time.

Crystal Veil Mask Bokin 24 is designed to ensure that face masks remain clean and hygienic. While people that wear face masks often worry about whether or not the masks are still hygienic after prolonged use, spraying Crystal Veil Mask Bokin 24 on the mask prior to use provides a sustained antimicrobial effect. Spraying the mask just once prevents viruses and bacteria from adhering to the mask surface for a period of approximately 24 hours.

Etak, the main ingredient in the new spray, is a long-acting antimicrobial agent containing both antimicrobial and adhesive substances that was developed by Professor Hiroki Nikawa of the Department of Oral Health Engineering at Hiroshima University's Graduate School of Biomedical Sciences. The adhesive ingredient in Etak chemically binds to sprayed surfaces, thereby ensuring that the bactericidal ingredient provides a prolonged antimicrobial effect even after the agent dries. Crystal Veil Mask Bokin 24 helps ensure that face masks remain clean and hygienic for a prolonged period of time through the simple action of spraying, thereby providing consumers who wear them with a sense of reassurance. Eisai remains committed to ensuring the delivery of products that satisfy the diversified needs of consumers and to making further contributions to increase the benefits provided to them. * This product is not effective against all types of bacteria and viruses.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120 

Copyright 2012 JCN Newswire. All rights reserved. www.japancorp.net